Selective inhibitor shows early promise in patients with RET-altered cancers

BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well tolerated and had broad clinical benefit in patients with advanced cancer that had progressed on previous therapies including multikinase inhibitor therapy. Proof-of-concept data will be presented from an ongoing phase I clinical trial at the AACR Annual Meeting 2018, April 14-18, in Chicago. “RET-altered cancers […]

Continue reading »

Novel drug shows promise against acute myeloid leukemia

In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and […]

Continue reading »

Research shows child welfare social workers lack consistency when helping at-risk children

Differing perceptions of risk among child welfare social workers is leading to inconsistent outcomes for children in need, a University of Otago-led study reveals. Lead author, Senior Lecturer in Social Work Dr. Emily Keddell, says children in similar circumstances can receive variable interventions or decisions from child welfare services because of social workers’ different perceptions of risk, safety and future […]

Continue reading »
1 3 4 5